Tirzepatide is a novel medication that the FDA has approved to treat type 2 diabetes mellitus. Tirzepatide is used off-label to treat obesity because` of its powerful weight-loss effects. It Known as the "twin epidemics," the prevalence of obesity and diabetes is a growing issue worldwide, particularly in wealthy nations. Therefore, cutting-edge therapeutic strategies are required. Tirzepatide, Known as a "twincretin," tirzepatide is the only dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonist that is considered a "first-in-class" medication. It has the ability to significantly lower blood sugar levels and enhance insulin sensitivity, as well as improve lipid metabolism and reduce body weight by more than 20%. To enhance the advantages of GLP-1 drugs like semaglutide, it functions as a dual GLP-1 agonist and GIP agonist.. It is currently administered as a once-weekly subcutaneous injectable as a second-line diabetic medicine, much as GLP-1 drugs. In May 2022, Tirzepatide received FDA approval. The gastrointestinal side effects, such nausea or diarrhea, are the most frequently reported side effects..This exercise goes over the tirzepatide dosage guidelines, mechanism of action, side effects, contraindications, and key information. It also emphasizes for all practitioners the tirzepatide administration, monitoring, and toxicity connected with the drug. With a C20 fatty acid segment added, this novel anti-diabetic drug is a synthetic peptide mimic of the human GIP hormone. Using acylation technology, it can bind to albumin and provide a weekly subcutaneous injection dose of the medication that is suitable for its roughly five-day half-life.
